Affiliations 

  • 1 Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  • 2 Department of Microbiology, University of Hong Kong, Hong Kong, China
  • 3 Department of Medicine, Faculty of Medicine, MAHSA University, Jenjarom, Selangor, Malaysia
  • 4 Department of Pulmonology, Calcutta Medical Research Institute, Kolkata, India
  • 5 Tampines Family Medicine Clinic, Mission Medical Clinic, Hougang, Singapore
  • 6 Emerging Markets Medical Affairs, Vaccines, Pfizer Inc, San Jose, Costa Rica
  • 7 Emerging Markets Medical Affairs, Vaccines, Pfizer Pte Ltd., Singapore, Singapore
Hum Vaccin Immunother, 2024 Dec 31;20(1):2417554.
PMID: 39478351 DOI: 10.1080/21645515.2024.2417554

Abstract

This narrative review describes pneumococcal serotype prevalence for invasive disease and carriage and antibiotic resistance among specimens collected from children in countries across South and Southeast Asia from 2012 to 2024. Literature search retrieved 326 articles; 96 were included. The prevalence of pneumococcal serotypes varied geographically and over time after introduction of pneumococcal conjugate vaccine. Serotypes common in both pneumococcal carriage and disease were 6A, 6B, 14, 15B/15C, 19F, and 23F; serotypes 1, 3, 5, 19A, 15A, 10A, and 35B were also common in disease. Most of these serotypes are included in the 13-valent and 10-valent PCV. Carriage and disease isolates remained generally highly susceptible to vancomycin (mostly 100%) and levofloxacin (mostly >97%). These findings indicate that vaccine-preventable serotypes contribute significantly to pneumococcal disease burden in children in South and Southeast Asia. Consistency of national immunization programs with World Health Organization recommendations may reduce rates of pneumococcal disease in this region.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.